Supplementary Figure 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 2. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 33; R/R AML; FHD-286 2.5 mg QD dose group.
Authors: Courtney D. DiNardo, Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás-Cardama, Sarah A. Reilly, Caroline Almon, Caitlin Patriquin, Salah Nabhan, Kathleen Healy, Denice Hickman, Michael P. Collins, Alexis Khalil, Dillon Corrigan, Tina Zhao, Jessica Piel, Kelly Lyons, Kim Horrigan, Virna Schuck, Paul Martin, GiNell Elliott, David L. Lahr, Mia Bosinger, Katie D’Aco, Gromoslaw Aleksander Smolen, Martin Hentemann, Sanam Loghavi, Samuel Agresta, Michael R. Savona, Eytan M. Stein
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4411285613